In 2 large databases, algorithms applied to prescription data had varying accuracy in identifying increased risk of adverse opioid-related events.
monitoring programs administered by many states to record information on medications scheduled by the US Drug Enforcement Agency.
Health insurance claims databases can have tremendous value in detecting patterns of aberrant behaviors with prescription opioids because they comprehensively capture longitudinal information on the dispensing of prescription medications in addition to diagnoses, procedures, and other health care services.
Multiple algorithms have been proposed to detect aberrant behaviors with prescription opioids by using insurance claims data.
As part of their Overutilization Monitoring System, 9 the Centers for Medicare and Medicaid Services (CMS) created an algorithm to identify "overuse" of prescription opioids. The algorithm was implemented in Medicare Part D in 2014 to identify beneficiaries who may require individualized safety measures, such as restrictions on prescribers or pharmacies for scheduled drugs. Several academic research groups have also proposed algorithms to detect aberrant behaviors with prescription opioids. [10] [11] [12] [13] However, the ability of existing algorithms to successfully identify individuals at risk for adverse events has not been compared and there is a lack of consensus on which criteria should be used to identify aberrant behaviors with prescription opioids from administrative prescription data.
14 Therefore, the primary objective of our study was to validate and compare the performance of 5 previously published algorithms. We 
| Study population
We included all new users of prescription opioids (ie, no record of previous use for at least 6 months before initiating treatment), who were over 15 years old, had no diagnosed malignancy, and had no history of opioid abuse or dependence in the 6 months prior to the first dispensed opioid prescription. We considered the dispensing of oral and transdermal opioid analgesics; injectable opioid formulations and buprenorphine were excluded (see Appendix Table A1 for a full list of included compounds). We defined the index date as the date of the initial opioid prescription dispensing and required insurance coverage to extend from 6 months before the index date through 12 months after the index date (to allow adequate time for assessment of algorithm criteria). Baseline patient characteristics, including demographics, use of health care services, diagnosis of pain conditions, comorbid mental health conditions, and use of psychotropic medications, were measured during the 6 months up to and including the index date.
We deliberately chose to include all new users of prescription opioids in this analysis for several reasons. Most importantly, it reflects how we anticipate these algorithms will be used in practice. Furthermore, even patients with a single opioid prescription are at some risk for opioid-related adverse events. Finally, the primary purpose of this study was to evaluate whether people who met triggering criteria of each of the algorithms had opioid-related adverse events. Each of the algorithms already implicitly requires more than 1 prescription to trigger a positive result.
| Algorithms to identify aberrant behaviors with prescription opioids
We consider aberrant behaviors to be "a constellation of behaviors that have grown to be recognized by clinicians as potentially indicative of prescription opioid abuse," as defined by a Tufts Health Care Institute expert panel. 15 In addition to CMS' Overutilization Monitoring System, 9 we identified 4 additional algorithms from the peer-reviewed literature: the Opioid Misuse Score, 13 the Controlled Substance-Patterns of Utilization Requiring Evaluation (CS-PURE) algorithm, 12 the Katz et al. algorithm, 11 and the Cepeda et al algorithm. 10 We did not use a systematic search strategy to identify these algorithms.
We used prescription claims information on medication, dose, quantity dispensed, number of days supplied, prescribing physician, pharmacy, and date of dispensing during the 12 months following the index date to identify aberrant behaviors according to each
KEY POINTS
• With tens of thousands of fatal overdoses involving opioids annually, algorithms to detect aberrant opioid use from administrative data will have increasingly important applications in surveillance, research, and public health interventions.
• Our study examines the performance of existing algorithms, demonstrating their strengths and weaknesses. These algorithms had not been previously compared.
• The agreement of the algorithms was poor to moderate.
All 5 algorithms generally had high specificity and negative predictive value, but low sensitivity and positive predictive value.
• Our findings justify further work to improve the capabilities of algorithms to detect aberrant behaviors with opioids. 16, 17 In sensitivity analyses to ensure high specificity of the outcome measure, we further restricted the definition to opioid poisoning alone, which has a positive predictive value of 96% for opioid-related adverse events. 
18
The absolute risk of an opioid-related adverse event for patients meeting each definition was calculated, along with unadjusted risk differences and corresponding 95% confidence intervals comparing patients who met and did not meet each definition. Sensitivity, specificity, positive predictive value, and negative predictive value were also calculated, comparing all the algorithms to a uniform benchmark of opioid-related adverse event diagnoses.
All analyses were conducted by using SAS version 9.4 (SAS Institute, Cary, North Carolina).
| RESULTS
The study sample consisted of 3. 
TABLE 1 Algorithms to identify aberrant behaviors with prescription opioids from insurance claims data

Algorithm Name Description
Original Algorithm Timeframe CMS overutilization monitoring system ≥120 mg of average morphine equivalents for ≥90 consecutive days 3 months AND > 3 prescribers for any opioid drug AND > 3 pharmacies for any opioid drug Opioid misuse score For each 6-month (180 day) period:
12 months (2 6-month periods) Days supplied of IR/SA opioids: "0" points if ≤185 days, "1" point if 186-240 days, "2" points if >240 days Days supplied of ER/LA opioids: "0" points if ≤185 days, "1" point if 186-240 days, and "2" points if >240 days Number of pharmacies for opioids: "0" points if 0-2 pharmacies, "1" point if 3-4 pharmacies, and "2"
points if ≥5 pharmacies Number of prescribers of opioids: "0" points if 0-2 prescribes, "1" point if 3-4 prescribers, and "2" points if ≥5 prescribers Scores for both periods are summed and classified as follows: no misuse (0-1 points), possible misuse (2-4 points), and probable misuse (≥5 points) Table 2 in CDM).
Sensitivity analyses using only opioid poisoning codes to define opioid-related adverse events did not substantially alter conclusions. 
| DISCUSSION
Algorithms that can identify potentially aberrant behaviors from electronic databases may be useful tools to combat the prescription opioid epidemic, with possible applications including triggers for early intervention, surveillance, and policy evaluation. We compared the performance of 5 existing algorithms designed to detect aberrant behaviors with prescription opioids in large cohorts of publicly and commercially The original CS-PURE contains 10 items to identify possible aberrant behaviors related to multiple controlled substances. Only CS-PURE criteria related to prescription opioid compounds were retained for this analysis.
insured patients. Each algorithm was able to identify patients who were at a statistically significant increased risk of an adverse opioidrelated event. Despite differences in patient characteristics and overall prevalence of opioid-related adverse events, algorithms had similar performance in the MAX and CDM datasets.
Despite each algorithm's ability to identify patients who were at increased risk, they shared some important limitations; sensitivity was generally low, and many patients who would go on to develop an opioid-related adverse event never displayed prescription patterns that were classified as "aberrant." This observation may partially reflect limitations in our data sources, including the inability of prescription claims data to capture illicit acquisition of opioids. Given the demonstrated differences in performance, some algorithms may be more appropriate for specific contexts depending on the relative importance of incorrectly classifying a patient as having aberrant patterns (ie, desiring high specificity) versus failing to detect problematic behaviors (ie, desiring high sensitivity). If an algorithm was being used to target harm reduction interventions such as naloxone distribution, sensitivity would likely be prioritized over specificity to minimize the number of potentially preventable adverse events that would be overlooked. In contrast, high specificity would be more important for any intervention used to limit access to prescription opioids to avoid creating undue burden on patients experiencing pain who are at low risk of an adverse event. Policy makers must carefully consider individual algorithm strengths and limitations alongside legal and ethical concerns, including how false positive and false negative algorithm classifications will impact patient safety, privacy, and behavior.
The prevalence of aberrant behaviors with prescription opioids was generally low within the first year of initiating opioid use, except when defined using the Katz algorithm. We also found that the incidence of aberrant behaviors and of opioid-related adverse events was elevated in the MAX cohort compared with the CDM cohort, though these disparities are likely due to underlying differences in each cohort's population. Groups that tend to have elevated risk of opioid abuse had greater representation in MAX, including young people, patients with mental health comorbidities, and individuals with other underlying substance abuse problems. 19, 20 Our study has several limitations. First, records for any opioid prescriptions purchased without using insurance benefits will be missing from the MAX and CDM databases. In one large US-based study, approximately 19% of patients who dispensed a Schedule II opioid had at least 1 cash transaction. 21 As a result, some patients in this study who purchased prescription opioids using cash may be misclassified as not meeting a given algorithm. Second, the CMS' introduction of a policy requiring the redaction of substance abuserelated claims 22, 23 
